Table 4.

Pharmacokinetics of GTDS, i.v. granisetron, and oral moxifloxacin during 5 days of study, overall and by gender

AllMaleFemale
Geometric mean%CVGeometric mean%CVGeometric mean%CV
GTDS
N59a3029
Cmax, ng/mL3.62983.302.90879.144.56378.15
Tmax, hb56.08 (23.82–119.83)56.08 (23.83–119.83)71.83 (23.82–119.83)
 AUC0–120h, ng · h/mL238.589.48193.485.51296.384.15
Intravenous granisetron
N59c3128
Cmax, ng/mL4.94858.125.00372.474.88729.78
Tmax, hb0.57 (0.02–2.12)0.33 (0.02–2.08)0.58 (0.02–2.12)
 AUC0–infinity, ng · h/mL36.8763.2932.6362.7442.2261.12
Oral moxifloxacin
N602931
Cmax, ng/mL2,14826.501,82621.832,58219.32
Tmax, hb4.07 (1.08, 4.15)4.07 (1.08–4.08)2.08 (2.07–4.15)
 AUC0–24h, ng · h/mL24,88021.2721,69013.7228,28017.62

Abbreviation: %CV, percent coefficient of variation.

  • aPharmacokinetic parameters were not available for one subject.

  • bTmax: median (min, max).

  • cOne subject withdrew before receiving granisetron injection.